Raphaël Ortiz

Företagsledare/Principal på TELIX PHARMACEUTICALS LIMITED

51 år

Consumer Services

Health Technology

Profil

Raphaël Ortiz is currently Chief Executive Officer-Telix International at Telix Pharmaceuticals Ltd. since 2024 and Co-Managing Director at Rhine Pharma GmbH.
Formerly, Mr. Ortiz was Head-Asia Pacific Cluster at Advanced Accelerator Applications SA. Education includes graduate degrees from the University of Seville and the University of Reims Champagne-Ardenne, and an MBA from Kenan-Flagler Business School.

Aktiva positioner av Raphaël Ortiz

Företag	Position	Start
TELIX PHARMACEUTICALS LIMITED	Företagsledare/Principal	2022-01-01

Alla aktiva positioner av Raphaël Ortiz

Tidigare kända positioner av Raphaël Ortiz

Företag	Position	Slut
ADVANCED ACCELERATOR APPLICATION SA(ADR)	Företagsledare/Principal	-

Se detaljerna i Raphaël Ortizs erfarenhet

Raphaël Ortizs utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i Raphaël Ortizs erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	5
University of Seville University of Seville Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Reims Champagne-Ardenne University of Reims Champagne-Ardenne Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Advanced Accelerator Applications SA Advanced Accelerator Applications SA Pharmaceuticals: MajorHealth Technology Develops and produces nuclear medicine and radioligand therapies	Health Technology
Kenan-Flagler Business School Kenan-Flagler Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Ltd. BiotechnologyHealth Technology Operates as a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals	Health Technology